Compare IMUX & HELP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IMUX | HELP |
|---|---|---|
| Founded | 2016 | N/A |
| Country | United States | Canada |
| Employees | 66 | 50 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 209.2M | 233.0M |
| IPO Year | 2013 | N/A |
| Metric | IMUX | HELP |
|---|---|---|
| Price | $14.99 | $7.05 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 2 |
| Target Price | $36.00 | ★ $51.50 |
| AVG Volume (30 Days) | 174.0K | ★ 1.5M |
| Earning Date | 05-14-2026 | 07-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 38.00 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.51 | $3.76 |
| 52 Week High | $15.84 | $8.55 |
| Indicator | IMUX | HELP |
|---|---|---|
| Relative Strength Index (RSI) | 59.12 | 69.17 |
| Support Level | $0.74 | $5.77 |
| Resistance Level | $15.81 | $8.55 |
| Average True Range (ATR) | 0.82 | 0.48 |
| MACD | -0.14 | 0.06 |
| Stochastic Oscillator | 51.75 | 80.12 |
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.
Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds.